Infinity, Mundipharma, Purdue Pharma deal

Purdue and Mundipharma exercised an option for exclusive, worldwide rights to the fatty acid amide hydrolase (FAAH) pain program from Infinity. Purdue plans to start Phase II testing next year for th...